492.69
-9.86 (-1.96%)
| Penutupan Terdahulu | 502.55 |
| Buka | 504.79 |
| Jumlah Dagangan | 1,246,811 |
| Purata Dagangan (3B) | 1,450,556 |
| Modal Pasaran | 126,517,862,400 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.12 |
| Harga / Jualan (P/S) | 11.99 |
| Harga / Buku (P/B) | 8.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Keuntungan | -4.86% |
| Margin Operasi (TTM) | 44.98% |
| EPS Cair (TTM) | -2.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 15.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -5.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.66% |
| Nisbah Semasa (MRQ) | 2.69 |
| Aliran Tunai Operasi (OCF TTM) | -492.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.73 B |
| Pulangan Atas Aset (ROA TTM) | 12.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Vertex Pharmaceuticals Incorpor | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.11% |
| % Dimiliki oleh Institusi | 96.58% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 567.00 (B of A Securities, 15.08%) | Beli |
| Median | 467.00 (-5.21%) | |
| Rendah | 420.00 (RBC Capital, -14.75%) | Pegang |
| Purata | 484.55 (-1.65%) | |
| Jumlah | 5 Beli, 6 Pegang | |
| Harga Purata @ Panggilan | 459.29 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 01 Apr 2025 | 420.00 (-14.75%) | Pegang | 492.69 |
| 20 Feb 2025 | 408.00 (-17.19%) | Pegang | 480.33 | |
| B of A Securities | 31 Mar 2025 | 567.00 (15.08%) | Beli | 492.69 |
| Canaccord Genuity | 12 Feb 2025 | 424.00 (-13.94%) | Pegang | 453.20 |
| Barclays | 11 Feb 2025 | 467.00 (-5.21%) | Pegang | 455.22 |
| Cantor Fitzgerald | 11 Feb 2025 | 480.00 (-2.58%) | Beli | 455.22 |
| 31 Jan 2025 | 480.00 (-2.58%) | Beli | 461.68 | |
| HC Wainwright & Co. | 11 Feb 2025 | 550.00 (11.63%) | Beli | 455.22 |
| 31 Jan 2025 | 550.00 (11.63%) | Beli | 461.68 | |
| Morgan Stanley | 11 Feb 2025 | 459.00 (-6.84%) | Pegang | 455.22 |
| Scotiabank | 11 Feb 2025 | 450.00 (-8.66%) | Pegang | 455.22 |
| 31 Jan 2025 | 433.00 (-12.12%) | Pegang | 461.68 | |
| Truist Securities | 11 Feb 2025 | 520.00 (5.54%) | Beli | 455.22 |
| Wells Fargo | 30 Jan 2025 | 460.00 (-6.64%) | Pegang | 438.40 |
| 10 Jan 2025 | 460.00 (-6.64%) | Beli | 409.56 | |
| Piper Sandler | 27 Jan 2025 | 533.00 (8.18%) | Beli | 443.88 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |